Investment Summary

Eight Roads Invests In J-Pharma

On January 7, 2021, private equity firm Eight Roads invested in life science company J-Pharma

Investment Highlights
  • This is Eight Roads’ 62nd transaction in the Life Science sector.
  • This is Eight Roads’ 24th transaction in Japan.

Investment Summary

Date 2021-01-07
Target J-Pharma
Sector Life Science
Investor(s) Eight Roads
Deal Type Venture

Target

J-Pharma

Tokyo, Japan
J-Pharma develops therapeutics and diagnostic agents for treatment of cancer. J-Pharma was founded in 2005 and is based in Tokyo, Japan.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Eight Roads

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1969
PE ASSETS 11.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.


DEAL STATS #
Overall 242 of 293
Sector: Life Science M&A 62 of 73
Type: Venture M&A Deals 219 of 266
Country: Japan M&A 24 of 25
Year: 2021 M&A 2 of 29
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-05 TradeBlock

Stamford, Connecticut, United States

TradeBlock is a crypto index provider. TradeBlock offers advanced indexes and reference rates, consolidated APIs, historical trade and order-book data, and customizable algorithms. TradeBlock was founded in 2013 and is based in Stamford, Connecticut.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-04 Sana Biotechnology

Seattle, Washington, United States

Sana Biotechnology is focused on creating and delivering engineered cells as medicines for patients. Sana Biotechnology offers to repair and controlling genes, replacing missing or damaged cells, and making therapies broadly available to patients. Sana Biotechnology was founded in 2018 and is based in Seattle, Washington.

Sell -